000			03364nam a22003855i 4500
001			289152
003			MX-SnUAN
005			20160429154659.0
007			cr nn 008mamaa
008			150903s2010 xxu| o |||| 0|eng d
020			_a9781603272711 _99781603272711
024	7		_a10.1007/9781603272711 _2doi
035			_avtls000343207
039		9	_a201509030903 _bVLOAD _c201405050253 _dVLOAD _y201402061150 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRC261-271
100	1		_aPolunovsky, Vitaly A. _eeditor. _9319224
245	1	0	_amTOR Pathway and mTOR Inhibitors in Cancer Therapy / _cedited by Vitaly A. Polunovsky, Peter J. Houghton.
264		1	_aTotowa, NJ : _bHumana Press : _bImprint: Humana Press, _c2010.
300			_axii, 304 páginas _brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aCancer Drug Discovery and Development
500			_aSpringer eBooks
505	0		_amTORC1: A Signaling Integration Node Involved in Cell Growth -- The Regulation of the IGF-1/mTOR Pathway by the p53 Tumor Suppressor Gene Functions -- mTOR Signaling in Angiogenesis -- mTORC1 Signaling and Hypoxia -- mTOR Signaling in Glioblastoma: Lessons Learned from Bench to Bedside -- mTOR and Cancer Therapy: General Principles -- mTOR and Cancer Therapy: Clinical Development and Novel Prospects -- Drug Combinations as a Therapeutic Approach for mTORC1 Inhibitors in Human Cancer -- Downstream Targets of mTORC1 -- Downstream of mTOR: Translational Control of Cancer -- Genome-Wide Analysis of Translational Control -- Translational Control of Cancer: Implications for Targeted Therapy -- Downstream from mTOR: Therapeutic Approaches to Targeting the eIF4F Translation Initiation Complex.
520			_amTOR Pathway and mTOR Inhibitors in Cancer Therapy provides an up-to-date survey of the rapidly advancing field of cancer therapy. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment – targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. In this work, experts in TOR signaling have contributed in two thematic areas: mTOR Signaling and Cancer Therapy (chapters 1 - 8) and Therapeutic Targeting Downstream of mTOR (chapter 9 – 13). All chapters of mTOR Pathway and mTOR Inhibitors in Cancer Therapy are completely new or have been extensively updated by their authors; and we are indebted to all authors who have exemplified the links between these 2 thematic areas.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aHoughton, Peter J. _eeditor. _9304965
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9781603272704
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-60327-271-1 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c289152 _d289152